The optimal treatment for patients with advanced-stage Hodgkin lymphoma is an ongoing controversy. A recent trial seemed to answer some of the important open questions in the field; however, closer examination of the data indicates that the answers are not as clear as they might initially seem.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Diehl, V. et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N. Engl. J. Med. 348, 2386–2395 (2003).
Engert, A. et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J. Clin. Oncol. 27, 4548–4554 (2009).
Canellos, G. P. et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N. Engl. J. Med. 327, 1478–1484 (1992).
Duggan, D. B. et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J. Clin. Oncol. 21, 607–614 (2003).
Federico, M. et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J. Clin. Oncol. 27, 805–811 (2009).
Borchmann, P. & Engert, A. The past: what we have learned in the last decade. Hematology Am. Soc. Hematol. Educ. Program 2010, 101–107 (2010).
Viviani, S. et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N. Engl. J. Med. 365, 203–212 (2011).
Diehl, V. et al. Should the treatment of advanced Hodgkin Lymphoma patients be a question of faith or a question of medical science? N. Engl. J. Med. (in press).
Santoro, A. et al. Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J. Clin. Oncol. 5, 27–37 (1987).
US National Library of Medicine. ClinicalTrials.gov [online], (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Borchmann, P., Engert, A. & Diehl, V. Hodgkin lymphoma—absence of evidence not evidence of absence!. Nat Rev Clin Oncol 8, 636–637 (2011). https://doi.org/10.1038/nrclinonc.2011.149
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.149
